Ozempic Lawsuits Have Been Centralized in Pennsylvania Court
Recently, the United States Judicial Panel on Multidistrict Litigation centralized the Ozempic lawsuits, at least 55 of them, in Pennsylvania federal court. These lawsuits allege that defendants Novo Nordisk and Eli Lilly failed to warn people of severe side effects linked to the diabetes and weight loss drugs Ozempic and Mounjaro. The plaintiffs allege they were prescribed drugs to treat diabetes or assist in weight loss but weren’t warned about serious side effects like stomach paralysis and intestinal obstruction. If you were harmed by Ozempic or Mounjaro, call the seasoned Chicago-based product liability lawyers of Moll Law Group. Billions have been recovered in product liability cases with which we’ve been involved around the country.
Consult Moll Law Group About Your Ozempic Claim
In its order, the JPML agreed it would send all the Ozempic and Mounjaro cases to United States District Judge Gene E.K. Pratter in the Eastern District of Pennsylvania where 13 of the cases were already pending. The JPML believes the drugs are similar enough that one MDL for the cases would make discovery and other proceedings more efficient; it will also avoid the risk of inconsistent rulings. Judge Pratter can issue rulings and make consistent decisions that apply to side effect cases related to the relevant diabetes and weight loss drugs.
The defendant pharmaceutical companies denied the allegations in court and moved to dismiss the lawsuits on the grounds that the drugs’ potential side effects are known to the public and that the labels on the drugs announce the side effects, thereby providing adequate warnings.